Packer Forbes Communications is to handle a campaign to promote the fact Amgen has secured expanded European marketing approval for Aranesp, one of the firm’s main sales drivers.
Aranesp can now be injected once every three weeks to treat anaemia – a blood deficiency resulting in pallor or weariness – in adult cancer sufferers with non-myeloid malignancies who are receiving chemotherapy.
Dosing was formerly once-weekly but Aranesp can now be given at the same time as a patient’s chemotherapy doses – a more convenient dosing regimen.
Around 70 per cent of all patients undergoing chemotherapy suffer from anaemia.
Packer Forbes, which has never formerly worked with Amgen, aims to ‘work closely with’ cancer-related charities.
Its PR work will kick off at the European Society for Medical Oncology conference in Vienna on 29 October.
Chandler Chicco Agency continues to hold the global and US PR contracts for Aranesp.
Aranesp was formerly promoted in the UK by CPR UK but that agency ceased to represent the brand 12 months ago.